obtain

Soft2Bet granted Ontario Certification of Registration and readies for imminent launch

Source Node:
Time Stamp: April 10, 2024 1:51 PM - Modified On: April 10, 2024 - Published By:
Source Cluster:
Republished By Plato

Ontario Certificate is hugely promising as Soft2Bet continues its regulatory expansion Soft2Bet, a leading provider of online betting and gaming solutions to regulated operators worldwide, is delighted to announce that it has been granted a Certificate of Registration in Ontario, Canada’s largest province, moving it one step closer to being able to launch its Tooniebet.com iGaming brand. Obtaining its Certificate of Registration (Nbr: OPIG1280338) from the Alcohol and Gaming Commission of Ontario (AGCO) will enable Soft2Bet to continue its expansion into the world’s largest regulated jurisdictions. Ontario has been a

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

FTX Trading Bankruptcy: Protecting Your Company’s Interests.

Source Node:
Time Stamp: February 1, 2023 3:22 PM - Modified On: February 1, 2023 - Published By:
Source Cluster:
Republished By Plato

Zuber Lawler is representing entities who received investments from Alameda Research and FTX Ventures. Alameda Research and several other FTX-related entities have filed bankruptcy proceedings in Delaware. These multiple filings are all being administered under one matter, In re FTX Trading, USBC Case No. 22-11068. Most first and second day motions have been heard and either have been granted or are currently pending. Things are moving forward. On January 18, 2023, FTX debtors moved for an order authorizing and approving procedures for a sale or transfer of what they have